Podcasts about medical oncology

In this special WCLC 2026 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu recap key findings from day three of the conference, featuring major advances that move targeted therapies earlier in the treatment of lung cancer. Guests Dr. Julia Rotow, Dr. Roy Herbst, and Dr. Daniel Tan discuss new data from DESTINY-Lung04, ADAURA, and REZILIENT3 and what these findings could mean for clinical practice. Guests: Dr. Julia Rotow Clinical Director and Research Director, Lowe Center for Thoracic Oncology Dana-Farber Cancer Institute Dr. Roy Herbst Director, Dartmouth Cancer Center Professor, Geisel School of Medicine at Dartmouth Dr. Daniel Shao-Weng Tan Senior Consultant Medical Oncologist at Division of Medical Oncology, National Cancer Centre Singapore Professor, Duke-NUS Medical School Senior Clinician-Scientist, Genome Institute of Singapore

Cancer is often seen as a disease that comes with age. But in Singapore, more teenagers and young adults are now being diagnosed with cancer. So, what’s driving this trend, how worried should we really be, and should younger Singaporeans be thinking differently about cancer prevention and early detection? On The Agenda, Hongbin Jeong speaks to Dr Eileen Poon, Medical Lead, Adolescent and Young Adults Oncology (AYAO) Programme and Senior Consultant, Division of Medical Oncology, National Cancer Centre Singapore to find out more.See omnystudio.com/listener for privacy information.

In this podcast episode, Hope S. Rugo, MD, FASCO, and Nerea Lopetegui-Lia, MD, discuss practice-informing data presented at ASCO 2026 for patients with early-stage hormone receptor (HR)–positive/HER2-negative breast cancer, including:Findings from the OPTIMA trial evaluating Prosigna gene expression testing to guide adjuvant chemotherapy decisions in patients with high-risk HR-positive/HER2-negative early breast cancerThe importance of ovarian function suppression plus endocrine therapy when considering chemotherapy-sparing strategies in premenopausal patientsResults from the NATALEE PAM50 biomarker analysis, showing ribociclib benefit across intrinsic subtypes with no significant treatment-by-subtype interactionPresenters:Hope S. Rugo, MD, FASCODirector, Women's Cancer ProgramDivision Chief, Breast Medical OncologyProfessor, Department of Medical Oncology & Therapeutics ResearchCity of Hope Comprehensive Cancer CenterProfessor Emeritus and Emeritus Winterhof Family Distinguished Professor of Breast OncologyUniversity of California, San FranciscoSan Francisco, CaliforniaNerea Lopetegui-Lia, MDAssistant ProfessorDivision of Medical Oncology, Breast SectionDepartment of Internal MedicineThe Ohio State UniversityColumbus, OhioGet access to all of our new podcasts by subscribing to the Decera Clinical Education [Oncology] Podcast on Apple Podcasts, YouTube Music, or Spotify.Link to full program: https://bit.ly/4x4u5AT Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Guest: Triparna Sen, PhD The 2026 World Conference on Lung Cancer (WCLC) is bringing together leaders, emerging investigators, and educational opportunities from across the lung cancer field. Dr. Triparna Sen sat down with us to share her perspective on how early-career clinicians and researchers can get the most out of their WCLC experience. She's the Max Morehouse Endowed Chair in Cancer Research and Associate Director of Research for the Division of Medical Oncology at The Ohio State University, as well as the Director of the Lung Cancer Preclinical Therapeutics Platform at The Ohio State University Comprehensive Cancer Center.

Guest: Triparna Sen, PhD The 2026 World Conference on Lung Cancer (WCLC) is set to spotlight pivotal research that could inform the next chapter of lung cancer care. Dr. Triparna Sen previews key phase III trials across small cell and non-small cell lung cancer, including emerging data on antibody-drug conjugates, targeted therapies, MRI surveillance, and adjuvant treatment, as well as sessions focused on biomarkers and liquid biopsy. Dr. Sen is the Max Morehouse Endowed Chair in Cancer Research and Associate Director of Research for the Division of Medical Oncology at The Ohio State University, as well as the Director of the Lung Cancer Preclinical Therapeutics Platform at The Ohio State University Comprehensive Cancer Center.

Guest: Triparna Sen, PhD How does the immune microenvironment change as EGFR-mutant lung adenocarcinoma develops treatment resistance and undergoes histologic transformation? In a recent study, multiomic spatial findings revealed broad immune suppression following transformation, including changes in T cells and immunosuppressive macrophages. Learn more with Dr. Triparna Sen, who shared these new findings at the 2026 World Conference on Lung Cancer. She's the Max Morehouse Endowed Chair in Cancer Research and Associate Director of Research for the Division of Medical Oncology at The Ohio State University, as well as the Director of the Lung Cancer Preclinical Therapeutics Platform at The Ohio State University Comprehensive Cancer Center.

Guest: Triparna Sen, PhD The 2026 World Conference on Lung Cancer (WCLC) is bringing together leaders, emerging investigators, and educational opportunities from across the lung cancer field. Dr. Triparna Sen sat down with us to share her perspective on how early-career clinicians and researchers can get the most out of their WCLC experience. She's the Max Morehouse Endowed Chair in Cancer Research and Associate Director of Research for the Division of Medical Oncology at The Ohio State University, as well as the Director of the Lung Cancer Preclinical Therapeutics Platform at The Ohio State University Comprehensive Cancer Center.

Guest: Triparna Sen, PhD The 2026 World Conference on Lung Cancer (WCLC) is set to spotlight pivotal research that could inform the next chapter of lung cancer care. Dr. Triparna Sen previews key phase III trials across small cell and non-small cell lung cancer, including emerging data on antibody-drug conjugates, targeted therapies, MRI surveillance, and adjuvant treatment, as well as sessions focused on biomarkers and liquid biopsy. Dr. Sen is the Max Morehouse Endowed Chair in Cancer Research and Associate Director of Research for the Division of Medical Oncology at The Ohio State University, as well as the Director of the Lung Cancer Preclinical Therapeutics Platform at The Ohio State University Comprehensive Cancer Center.

Guest: Triparna Sen, PhD How does the immune microenvironment change as EGFR-mutant lung adenocarcinoma develops treatment resistance and undergoes histologic transformation? In a recent study, multiomic spatial findings revealed broad immune suppression following transformation, including changes in T cells and immunosuppressive macrophages. Learn more with Dr. Triparna Sen, who shared these new findings at the 2026 World Conference on Lung Cancer. She's the Max Morehouse Endowed Chair in Cancer Research and Associate Director of Research for the Division of Medical Oncology at The Ohio State University, as well as the Director of the Lung Cancer Preclinical Therapeutics Platform at The Ohio State University Comprehensive Cancer Center.

In today's episode, we welcomed Sagar Lonial, MD, FACP, FASCO, to discuss the significance of the August 2026 FDA accelerated approval of iberdomide (Zenbexus) plus daratumumab and hyaluronidase-fihj (Darzalex Faspro) and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 1 prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. Dr Lonial is a professor and chair of the Department of Hematology and Medical Oncology at Emory University School of Medicine, as well as chief medical officer at Winship Cancer Institute of Emory University in Atlanta, Georgia. In the exclusive interview, Dr Lonial discussed the significance of the first approval of a CELMoD-based therapy for patients with multiple myeloma, detailed the key findings from the phase 3 EXCALIBER-RRMM trial (NCT04975997) that supported the regulatory decision, and expanded on how this combination regimen fits into the early relapse treatment paradigm.

In this episode of TOGA's Conversations in Lung Cancer Research, host A/Prof Mel Moore welcomes Prof Zarnie Lwin OAM (University of Queensland; Medical Oncologist at Royal Brisbane and Women's Hospital and The Prince Charles Hospital) to discuss her pathway from Burma to training in South Africa and Australia, and a two-year lung cancer fellowship at Princess Margaret Cancer Centre in Toronto. Prof Lwin reflects on choosing medical oncology, the value of leaving one's institution for fellowships, and how international training shaped her professionalism, networks, and research direction. She explains health services and qualitative research, highlighting a project interviewing interpreters that revealed cultural and language gaps around cancer and palliative care. The episode also covers equity-focused solutions (community and clinician education, in-person interpreters, cultural competency, and potential AI tools), challenges to clinical trial recruitment due to increasingly niche criteria and geographic distance, limited experience with teletrials, and her commitment to mentorship and humility in a rapidly evolving lung cancer field. 00:00 Welcome and Acknowledgement 00:37 Meet Professor Lwin 04:25 Training Across Countries 07:19 Choosing Medical Oncology 08:34 Medicine and Creativity 11:56 Fellowship Advice and Mentors 16:42 Health Services Research 19:06 Interpreters and Culture 25:40 Clinical Trial Barriers 30:43 Teletrials and Equity 32:29 Mentorship and Teaching 35:24 Episode Wrap Up ---------------Support TOGAThank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify.---------------Connect with TOGAAttend an Event: https://thoraciconcology.org.au/events/Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/Follow UsLinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/X (Twitter): https://x.com/TOGAANZInstagram: https://www.instagram.com/togaanz/YouTube: https://www.youtube.com/@Thoracic_Oncology---------------Acknowledgement of CountryThe Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

In collaboration with ROESCG, we introduce a new series, Cancer Careers! Today, we're joined by Dr. Natalie Levasseur, a Medical Oncologist at BC Cancer and Clinical Associate Professor in the Division of Medical Oncology at the University of British Columbia. Dr. Levasseur specializes in breast cancer oncology and is the current chair of the Provincial Breast Tumor Group in BC, the co-lead of the Breast Cancer Clinical Trials Unit in Vancouver, and serves on the BC Personalized Oncogenomics Steering Committee.

Live from Washington, Vassy Kapelos checks in with CTV National News Senior Political Correspondent Mike LeCouteur for the latest on trade. We also pick the brain of Lisa Raitt, a former Conservative Cabinet Minister and a member of Prime Minister Carney's Advisory Committee on Canada-USA Economic Relations. On today's show: Dr. Bishal Gyawali, a Medical Oncologist and Professor of Medical Oncology at Queen's University, reacts to new progress from Merck and Moderna on potential mRNA cancer vaccines. Talk Science To Me with CTV Science and Technology specialist Dan Riskin: The science of writing your dating-app bio. The Daily Debrief Panel - featuring Robert Benzie, Laura Stone, Marieke Walsh, and Mike LeCouteur. Afua Hagan, CTV News' Royal Commentator, reacts to reports of Prince Harry and Meghan Markle returning to the United Kingdom.

For many young women diagnosed with breast cancer, some of the most important decisions they will ever make happen within days of hearing the words, "You have cancer." While treatment planning begins immediately, patients may also be faced with urgent questions about fertility, future family-building, and preserving options they may not have expected to think about so soon. These conversations often happen during a period of fear, uncertainty, and information overload, leaving many patients feeling overwhelmed and unprepared. In this episode, I'm joined by Dr. Ann Partridge, Vice Chair of Medical Oncology and Chief Clinical Strategy Officer at Dana-Farber Cancer Institute, where she also serves as co-founder and director of the Program for Young Adults with Breast Cancer. A professor at Harvard Medical School, Dr. Partridge is a leading breast oncologist and researcher whose work focuses on improving care and outcomes for young adults with breast cancer. Together, we discuss how breast cancer treatment can affect fertility, why these conversations need to happen early, the options available today, and how patients can make informed decisions while balancing the urgency of cancer treatment with hopes and plans for the future. We also reinforce the hopeful message that having children after breast cancer is often possible - and that preserving future options begins with having the right conversations early. Most importantly, this episode is a reminder that patients deserve information, support, and compassionate guidance when facing life-changing decisions at diagnosis. Resources Mentioned in This Episode For additional information and support, visit the Young and Strong Program at Dana-Farber Cancer Institute, which offers resources and practical guides for young adults with breast cancer, including those who are newly diagnosed, in treatment, or in survivorship, as well as caregivers. The program also provides trusted information about fertility preservation, pregnancy after breast cancer, and breastfeeding. The information shared on Dear Cancer, I'm Beautiful is for educational and informational purposes only and is not intended as medical advice. Always consult your physician or qualified healthcare provider regarding your individual medical care and treatment decisions. The views and opinions expressed by guests are their own and do not necessarily reflect those of Cancer Fashionista. Thank you to Daiichi Sankyo and Novartis for making this episode of the Signature Series possible.

I am grateful to have Dr. Shabana Dewani join me for this conversation.The words “stage IV breast cancer” can bring an enormous amount of fear.But fear is often made worse by uncertainty and misconceptions.In Part 1 of our special three-part series on metastatic breast cancer, we go back to the basics: What exactly is metastatic breast cancer? How is it different from early-stage disease? Where can breast cancer spread? And what does a metastatic diagnosis really mean for someone's life and future?We also address some of the most common myths surrounding stage IV disease—including the belief that there are no treatment options or that someone with metastatic breast cancer will always look or feel sick.While metastatic breast cancer remains a serious diagnosis, treatment has evolved tremendously. Care is increasingly personalized to the biology of the cancer, with the goals of controlling disease, helping patients live longer, preserving quality of life, and managing symptoms.Most importantly, we talk about something every patient deserves from their medical team:Honesty and hope can exist together.If you or someone you love has recently been diagnosed with metastatic breast cancer, you do not need to have all the answers today.You are more than a stage.You are more than a scan.And you are not alone.We are both grateful to have conversations that elevate awareness and strengthen our community.Dr. Shabana Dewani  is board certified in Medical Oncology, Hematology, and Internal Medicine—and a joy to listen to!  She breaks down the oncology process and important factors when deciding treatment.  You'll be able to hear her passion for helping others ensuring they get the best treatment possible.Stay Connected with Dr. Deepa Halaharvi:TikTok: @breastdoctorInstagram: @drdhalaharviTBCP Instagram: @thebreastcancerpodcastWebsite: https://drdeepahalaharvi.com/YouTube: https://www.youtube.com/@deepahalaharvi5917Instagram: @thebreastcancerpodcast

In today's episode, we spoke with Jonathan Trent, MD, PhD, a professor in the Department of Medicine in the Division of Medical Oncology, associate director of Clinical Research, and the director of the Sarcoma Medical Research Program at the University of Miami Miller School of Medicine in Florida.In our exclusive interview, Dr Trent discussed currently approved TKIs for patients with gastrointestinal stromal tumor (GIST), including imatinib (Gleevec), sunitinib (Sutent), regorafenib (Stivarga), and ripretinib (Qinlock). Trent dove into how these TKIs have improved outcomes for patients and touched on common adverse effects seen with these therapies, as well as how to manage these toxicities and maintain treatment adherence among patients. He also looked to liquid formulations of TKIs that are in development and the benefits they would bring to GIST management. 

In the newest edition of Oncology On the Go, Joshua Richter, MD, and Marco Davila, MD, PhD, spoke about the current multiple myeloma treatment landscape and highlighted practical considerations for administering CAR T-cell therapy to patients. Their discussion touched upon several critical subtopics ranging from optimizing operational and referral workflows to dismantling barriers to treatment access in rural settings.When it comes to navigating the multiple myeloma treatment algorithm, both hosts emphasized early evaluation to determine patient suitability for CAR T-cell therapy, which may help identify those who are most likely to experience the greatest responses with minimal toxicity. Regarding the question of sequencing different modalities, Richter pointed to data demonstrating the utility of administering CAR T-cell therapies prior to bispecific antibodies.Acknowledging that the average patient enrolled on a clinical trial may not align with what is typically seen in real-world practice, the hosts discussed “reassuring” data that those who do not meet certain eligibility criteria may nevertheless benefit from CAR T-cell therapy. Additionally, on the topic of maintaining an effective referral relationship between community oncologists and CAR-T centers, Davila noted that academic cell therapy clinicians may have an incumbent responsibility to consider how to improve access to treatment and make it easier for others to refer patients to care.“CAR T-cell therapy is now deeply entrenched in the world of relapsed multiple myeloma [and] soon to be likely entrenched in the newly diagnosed world. These are therapies that I think we're all going to need to embrace whether it's from an academic standpoint or a community standpoint,” Richter concluded. “Having that ongoing communication back and forth, especially as the field is moving so quickly, is absolutely key in providing optimal care for our patients.”Richter is an associate professor of Medicine in the Division of Hematology and Medical Oncology at The Tisch Cancer Institute, as well as the director of Multiple Myeloma at the Blavatnik Family - Chelsea Medical Center at Mount Sinai. Davila is the senior vice president and associate director for Translational Research, a professor of Oncology, chief of Lymphoma/Multiple Myeloma Service, and Rustum Family Endowed Chair in Translational Research at Roswell Park Comprehensive Cancer Center.

Send us Fan MailNegative trials matter. In this episode, the Oncology Journal Club team discuss research that challenges established practice, alongside thought-provoking papers exploring how we communicate treatment goals in the era of immunotherapy and precision oncology.Professor Chris Jackson reviews the PERISCOPE II trial, showing that adding gastrectomy, cytoreductive surgery and HIPEC to systemic therapy does not improve survival for patients with gastric cancer and limited peritoneal metastases, while substantially increasing treatment-related morbidity.Dr Kate Clarke examines the NeoSUMMIT-01 trial, which provides further evidence supporting perioperative PD-1 inhibition alongside chemotherapy for gastric and gastro-oesophageal cancers, with encouraging improvements in event-free and overall survival.Professor Craig Underhill leads a discussion on a JAMA Oncology viewpoint questioning whether the traditional "curative" versus "palliative" treatment framework remains fit for purpose in modern oncology, particularly as immunotherapy and targeted therapies create new patterns of long-term survival.The team also explores:Smoking cessation programmes that improve outcomes for patients with cancer New ctDNA data following colorectal liver metastasectomy Steroids to reduce morphine-induced nausea and vomiting Highlights from the ASCO Breakthrough meeting The Lancet Oncology Commission on the global cancer workforce crisis Tumour-agnostic therapies and the challenges of equitable implementation Five-year follow-up from TOPAZ-1 in advanced biliary tract cancer A comprehensive review of recent advances in prostate cancer The Oncology Journal Club Podcast is hosted by Professor Craig Underhill, Dr Kate Clarke and Professor Chris Jackson, and proudly produced by The Oncology Network.Visit oncologynetwork.com.au for Show Notes, to send us Voice Notes and more information. 

Patients with ROS1-positive NSCLC have a new treatment option following the FDA approval of zidesamtinib for those previously treated with a ROS1 tyrosine kinase inhibitor. In this episode, Dr. Stephen Liu, Dr. Alexander Drilon, and Dr. Rosario Charo Garcia Campelo discuss the ARROS1 trial results, the drug's efficacy and safety profile, CNS activity, and where zidesamtinib may fit into current and future treatment strategies for ROS1-positive lung cancer. Guests: Alexander Drilon, MD Chief, Early Drug Development Service Attending Physician, Thoracic Oncology Service Memorial Sloan Kettering Cancer Center Professor, Weill Cornell Medical College Rosario Charo Garcia Campelo, MD Head of Medical Oncology and Thoracic Tumor Unit, Chair, University Hospital Head of the Oncology Research Group, Biomedical Research Institute A Coruna Spain

Open vs partial nephrectomy, and open vs robotic prostatectomy - two large randomised trials that did not change surgical practice! Just as important to examine these in GU Cast Journal Club as to examine pivotal trials that did change practice. Today we discuss the EORTC Today we discuss the EORTC 30904 RCT looking at kidney cancer surgery (Eur Urol 2011), and the Brisbane randomised trial of open vs robotic prostatectomy conducted (Lancet 2016). We are delighted to welcome back our GU Cast Journal Club Editors, Dr Carlos Delgado (Mexico City, MEX), and Dr Elena Berg (Munich, GER), along with main GU Cast Hosts, Renu Eapen and Declan Murphy. AN emotional one as Carlos is heading home to Mexico soon! Links to papers below:1. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma Eur Urol 2011 2. Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes from a randomised controlled phase 3 study Lancet 2016Even better on our YouTube channelAbout GU Cast Journal Club:Each month, two papers are discussed, each of which are of importance to the GU Oncology community. These may be recent papers, or occasionally we will chose a classic landmark paper in GU Oncology. The objective is to draw attention to important papers in GU Oncology, and critique these in a robust manner. The key target audience is trainees working in Urology, Medical Oncology, Radiation Oncology, Nuclear Medicine, and diagnostic specialties such as Radiology and Pathology. But any of our regular audience are likely to enjoy this Journal Club series.

Indolent systemic mastocytosis (ISM) is a rare form of systemic mastocytosis (SM) caused by an abnormal buildup of mast cells throughout the body. What causes ISM, and how is it diagnosed? In this episode, we speak with Aaron Gerds, MD, Associate Professor of Medicine in Hematology and Medical Oncology at the Cleveland Clinic Cancer Institute, about the signs and symptoms of ISM, the diagnostic process, and how ISM differs from other forms of systemic mastocytosis. We also hear from Candice Pauley, an ISM patient and co-host of the Mast Cast Pod, who shares her journey to diagnosis, her experience living with the disease, and the challenges of navigating a rare condition. Credits Host: Neha Pathak, MD, FACP, DipABLM Producer/Editor: Matt Stillo Show Notes: Lauren Summers Guests: Aaron Gerds, MD; Candice Pauley See omnystudio.com/listener for privacy information.

As cancer incidences continue to rise across the country. The Presidents of Ireland's cancer care representative bodies, along with the Irish Cancer Society, are warning that key parts of the care system are struggling to keep pace. Speaking to Anton was Dr Michael McCarthy the President of the Irish Society for Medical Oncology and is a signatory on the joint letter.

In today's episode, we welcomed Charles E. Geyer, MD, to discuss recent FDA approvals of fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) for the management of HER2-positive breast cancer. Dr Geyer is a professor of medicine and chief of Malignant Hematology and Medical Oncology in the Department of Medicine at the University of Pittsburgh and the University of Pittsburgh Medical Center Hillman Cancer Center in Pennsylvania.On May 15, 2026, the FDA approved T-DXd for the neoadjuvant treatment of adult patients with HER2-positive stage II or III breast cancer, as determined by an FDA-authorized test, followed by a taxane, trastuzumab (Herceptin), and pertuzumab (Perjeta); the regulatory agency simultaneously approved post-neoadjuvant T-DXd for the treatment of adult patients with HER2-positive breast cancer who have residual invasive disease after neoadjuvant HER2-targeted treatment.In our exclusive interview, Dr Geyer discussed the significance of these approvals, key data from the pivotal trials, and how these new indications for T-DXd are shaking up the HER2-positive breast cancer treatment paradigm.

Amanda King & Hari Kuhan Integrative oncologist Dr Hari Kuhan and metabolic nutritionist Amanda King join Jackie to talk metabolic therapy for cancer, why the ketogenic diet stresses cancer cells, and what’s in their new book, Metabolic Drugs for Cancer. “Apply the brakes on a growing cancer. Anything above that obviously is a blessing and brilliant, but that's the number one.” — Dr Hari Kuhan “The ketogenic diet causes stress on cancer cells, and stressed cancer cells are weaker.” — Amanda King About Hari Kuhan Dr Hari Kuhan completed his undergraduate medical training at Imperial College London, where he also obtained a BSc in Surgery and Anaesthesia. He carried out his foundation and core medical training in Central London, with appointments at St Mary’s Hospital and St Bartholomew’s Hospital. Over time, he built substantial expertise in Medical Oncology, working at leading institutions including St Bartholomew’s, University College London, and the Royal Marsden Hospital. He then pursued a research fellowship at Barts Cancer Institute, London funded by Stand Up to Cancer and HCA Healthcare, focusing on metabolic vulnerabilities in cancer stem cells and circulating tumour cells through the use of repurposed medicines and Vitamin C. Expanding his reach into translational and clinical development, Dr Kuhan joined the Sarah Cannon Research Institute UK (Harley Street), London where he served as lead sub-investigator on multiple Phase I and II solid tumour trials, and became adept at integrating next-generation sequencing outputs into therapeutic decision-making. Motivated by both scientific innovation and patient-centred care, Dr Kuhan co-founded Lucio Health with long-time associate Raphael Swery, united by a vision to reshape cancer care for the 21st century. Together, they established a clinic that integrates precision oncology, metabolic targeting, repurposed medicines, and evidence-based integrative strategies—pioneering a personalised model that moves beyond the limitations of conventional, one-size-fits-all approaches. At Lucio Health, cutting-edge AI-driven platforms interpret complex mutational and molecular data, while functional sensitivity testing of blood and tissue samples reveals how an individual’s cancer responds to a wide range of agents in real time. These insights are then integrated with metabolic and genomic profiling to create multi-layered, personalised roadmaps for each patient—designed not only to identify the most promising treatments, but also to avoid those unlikely to help. The ambition of Lucio Health is to bridge the gap between laboratory science and lived patient experience: translating the latest advances in genomics, artificial intelligence, and metabolic oncology into practical, compassionate, and highly individualised care pathways. It is a clinic built on the belief that cancer treatment should be as unique as the patient facing it, combining clarity and scientific precision with humanity and hope. About Amanda King After earning her BSc through the Open University that combined Human Biology with Psychology and Counselling, Amanda King advanced her clinical training through the College of Naturopathic Medicine in London, qualifying as a Nutritional Therapist in 2022 and as a Naturopathic Practitioner in 2024. Most recently, she completed the Practitioner Master Course in Integrative Metabolic Oncology with the Metabolic Terrain Institute of Health under Dr Nasha Winters, further deepening her expertise in terrain-focused cancer care. Over the past decade, Amanda has honed her practice at the intersection of nutrigenomics, methylation science and epigenetics, integrating advanced lab diagnostics with personalised nutrition, therapeutic ketogenic and ancestral diets, and targeted supplementation to optimise each patient’s metabolic landscape. A certified nutrigenomics practitioner with training in Integrative and Gestalt psychotherapy, she is widely regarded for translating complex genomic and hormonal data such as DNA methylation panels and DUTCH hormone testing into pragmatic nutrition and lifestyle protocols that address both biochemical individuality and psychological wellbeing. In her integrative oncology nutrition practice, Amanda delivers bespoke protocols that weave together diet, lifestyle optimisation, mindset coaching and evidence-based complementary therapies, empowering patients to navigate cancer with clarity and agency. Committed to reshaping the dialogue around food as medicine, she collaborates with metabolic oncologists, functional laboratories and patient-advocacy groups worldwide to expand access to precision, nutrition-centred oncology care and to generate rigorous outcome data that will elevate the standard of integrative cancer support. Amanda’s Top Tips       Prioritise your sleep — it affects everything else.       Try Byron Katie’s “The Work” (thework.com) to question your stressful thoughts when you wake at 3am.       Take regular breaks completely off-grid, away from your phone a Hari’s Top Tips       When a spark of inspiration to change something hits, ride it — don’t wait for the perfect moment.       Educate yourself about your condition: ask questions, look into your scan reports, tumour markers, mutations, and trial options rather than accepting “there’s nothing you can do.”       Make time to step away from the daily grind and be present with your family — don’t let life become just work and stress. Their Book Metabolic Drugs for Cancer – Amanda King and Dr Hari Kuhan Resources Mentioned       Hacking Chemo: Using Ketogenic Diet, Therapeutic Fasting and a Kickass Attitude to Power through Cancer – Martha Tettenborn       Loving What Is: Four Questions That Can Change Your Life – Byron Katie (referenced as “The Work,” thework.com)       The Metabolic Nutritionist Substack (Amanda’s, ~33,000 subscribers)       Optimized Health Substack (Amanda, co-written with Travis Christofferson) Connect with Amanda King       Website: amandakingnd.com (also: themetabolicnutritionist.com / linktr.ee/amandakingnd)       Instagram: @the.metabolic.nutritionist       Facebook: the.metabolic.nutritionist       LinkedIn: Amanda King       YouTube: @the.metabolic.nutritionist       Email: nutrition@amandakingnd.com Connect with Hari Kuhan       Website: luciohealth.com       Email: info@luciohealth.com The Fabulously Keto Diet & Lifestyle Journal: A 12-week journal to support new habits – Jackie Fletcher If you have enjoyed listening to this episode – Leave us a review By leaving us a review on your favourite podcast platform, you help us to be found by others. Connect with us on social media https://www.instagram.com/FabulouslyKeto1 https://twitter.com/FabulouslyKeto https://www.youtube.com/@FabulouslyKeto Facebook Group: https://www.facebook.com/groups/FabulouslyKeto Music by Bob Collum Recommend a guest We would love to know if you have a favourite guest you would like us to interview. Let us know who you would like to hear of if you have a particular topic you would like us to cover. https://fabulouslyketo.com/recommend-a-guest We sometimes get a small commission on some of the links, this goes towards the costs of producing the podcast.

Featuring perspectives from Dr Lyudmila Bazhenova and Dr Corey J Langer, including the following topics: Introduction (0:00) Therapeutic Approaches Targeting HER2 and RET — Dr Bazhenova (9:09) Therapeutic Approaches Targeting ALK and ROS1 — Dr Langer (31:56) CME information and select publications

Featuring perspectives from Dr Erika Hamilton, Dr Jane Lowe Meisel, Dr Joyce O'Shaughnessy and Dr Seth Wander, including the following topics: Introduction (0:00) Current and Future Management of HR-Positive, HER2-Negative Localized Breast Cancer — Dr Meisel(2:40) Optimizing First-Line Therapy for Patients with HR-Positive Metastatic Breast Cancer (mBC) — Dr Hamilton (36:57) Current and Future Role of Oral Selective Estrogen Receptor Degraders for Progressive HR-Positive mBC — Dr Wander (58:18) Clinical Utility of Agents Targeting the PI3K/AKT/mTOR Pathway for Patients with Progressive HR-Positive mBC — Dr O'Shaughnessy (1:18:00) CME information and select publications

Featuring perspectives from Dr Courtney D DiNardo and Dr Harry Paul Erba, including the following topics: Introduction (0:00) Current Management Approaches for FLT3- and IDH-Mutated Acute Myeloid Leukemia (AML) — Dr DiNardo (9:44) Current and Future Role of Menin Inhibitors for Patients with AML — Dr Erba (32:07) CME information and select publications

Featuring perspectives from Dr Mrinal Gounder and Dr Richard F Riedel, including the following topics: Introduction (0:00) Desmoid Tumors — Dr Gounder (2:58) Soft Tissue Sarcoma — Dr Riedel (28:29) CME information and select publications

Featuring perspectives from Dr Jonathan Goldman and Dr Zofia Piotrowska, including the following topics: Introduction (0:00) Current Management of Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) — Dr Goldman (0:38) Nonmetastatic EGFR-Mutated NSCLC, Exon 20 Insertion Mutations and Novel Agents — Dr Piotrowska (33:20) CME information and select publications

Featuring perspectives from Dr Anthony M Hunter and Dr Abdulraheem Yacoub, including the following topics: Introduction (0:00) Systemic Mastocytosis — Dr Hunter (9:33) Myelofibrosis — Dr Yacoub (29:40) CME information and select publications

Featuring perspectives from Dr Erika Hamilton and Dr Shanu Modi, including the following topics: Introduction (0:00) Considerations in the Care of Patients with Localized HER2-Positive Breast Cancer — Dr Modi (0:58) Contemporary Management of HER2-Positive Metastatic Breast Cancer — Dr Hamilton (25:51) CME information and select publications

Featuring perspectives from Dr Neeraj Agarwal and Dr Alan H Bryce, including the following topics: Introduction (0:00) Optimizing the Role of Hormonal Therapy in the Care of Patients with Prostate Cancer — Dr Bryce (2:41) Other Available and Emerging Therapeutic Approaches — Dr Agarwal (35:16) CME information and select publications

Featuring perspectives from Dr Kristen K Ciombor and Dr John Strickler, including the following topics: Introduction (0:00) Current and Future Role of Immune Checkpoint Inhibitors in the Management of Colorectal Cancer (CRC) — Dr Ciombor (3:58) Other Recent Advances in CRC Management — Dr Strickler (32:57) CME information and select publications

Featuring perspectives from Dr Adam M Brufsky and Dr Kevin Kalinsky, including the following topics: Introduction (0:00) Current and Future Role of TROP2-Directed Antibody-Drug Conjugates in Therapy for Triple-Negative Breast Cancer (TNBC) — Dr Brufsky (5:08) Established Treatment Paradigm for Localized and Metastatic TNBC — Dr Kalinsky (35:20) CME information and select publications

Featuring perspectives from Dr Deborah K Armstrong and Dr David M O'Malley, including the following topics: Introduction (0:00) PARP Inhibitors and Strategies Targeting Folate Receptor Alpha in Advanced Ovarian Cancer — Dr Armstrong (4:37) Other Novel Agents and Strategies for the Treatment of Advanced Ovarian Cancer — Dr O'Malley (35:18) CME information and select publications

Featuring perspectives from Dr Yelena Y Janjigian and Dr Samuel J Klempner, including the following topics: Introduction (0:00) Role of Anti-PD-1/PD-L1- and CLDN18.2-Directed Antibodies in the Management of Gastroesophageal Cancers — Dr Klempner (5:52) Management of HER2-Positive Gastroesophageal Cancers — Dr Janjigian (28:20) CME information and select publications

Featuring perspectives from Dr Terence Friedlander and Dr Daniel P Petrylak, including the following topics: Introduction (0:00) Role of Immunotherapeutic Strategies in the Management of Nonmetastatic Urothelial Bladder Cancer (UBC); Emerging Utility of Circulating Tumor DNA Evaluation — Dr Friedlander (3:53) Other Novel Agents and Strategies for Nonmetastatic and Metastatic UBC — Dr Petrylak (26:41) CME information and select publications

Featuring perspectives from Dr Hans Lee and Dr Noopur Raje, including the following topics: Introduction (0:00) Integrating Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies into the Management of Relapsed/Refractory Multiple Myeloma (R/R MM) — Dr Raje (4:30) Antibody-Drug Conjugates and Other Emerging Therapies for R/R MM — Dr Lee (28:33) CME information and select publications

Featuring perspectives from Dr John N Allan and Dr Adam Kittai, including the following topics: Introduction (0:00) Current Management of Newly Diagnosed Chronic Lymphocytic Leukemia — Dr Allan (8:47) Noncovalent Bruton Tyrosine Kinase Inhibitors and Other Novel Strategies — Dr Kittai (38:14) CME information and select publications

In collaboration with ROESCG, we introduce a new series, Cancer Careers! Today, we're joined by Dr. Chloe Lim, a 5th-year Medical Oncology Co-Lead Resident at the University of British Columbia. She takes us through how she co-founded the Learn Oncology podcast (the one you're listening to right now!), as well as her journey to Medical Oncology.

Featuring perspectives from Dr Eileen M O'Reilly and Dr Philip A Philip, including the following topics: Introduction (0:00) Optimal Incorporation of Chemotherapy into the Management of Advanced Pancreatic Cancer — Dr Philip (7:27) Other Available and Emerging Novel Approaches for Pancreatic Cancer — Dr O'Reilly (28:05) CME information and select publications

Featuring perspectives from Dr Manali Kamdar, Dr Krish Patel and Dr Gilles Salles, including the following topics: Introduction (0:00) Antibody-Drug Conjugates and Other Novel Strategies for the Management of Diffuse Large B-Cell Lymphoma (DLBCL) — Prof Salles (7:05) Current and Future Role of Monoclonal and Bispecific Antibodies in the Management of DLBCL — Dr Patel (26:21) Chimeric Antigen Receptor (CAR) T-Cell Therapy for DLBCL — Dr Kamdar (43:12) CAR T-Cell Therapy for Follicular Lymphoma (FL) — Prof Salles (1:08:33) Other Approved and Emerging Novel Therapies for FL — Dr Patel (1:24:44) Integrating Bispecific Antibodies into the Management of FL — Dr Kamdar (1:41:34) CME information and select publications

In this episode of Oncology Unplugged, host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was joined by Neil M. Iyengar, MD, an associate professor and co-director of Breast Medical Oncology in the Department of Hematology and Medical Oncology at the Emory University School of Medicine, as well as the director of Survivorship Services at the Winship Cancer Institute of Emory University in Atlanta, Georgia.Their conversation focused on the rapidly evolving treatment paradigm for triple-negative breast cancer (TNBC), the integration of metabolic health strategies, the clinical emergence of antibody-drug conjugates (ADCs) in the frontline metastatic setting, and the management of treatment-related toxicities.Drs Park and Iyengar examined data from the phase 3 TROPION-Breast02 trial (NCT05374512), which evaluated first-line datopotamab deruxtecan-dlnk (Dato-DXd; Datroway) in patients with PD-L1-negative metastatic TNBC. The trial demonstrated improvements in both progression-free survival and overall survival (OS) with Dato-DXd compared with standard chemotherapy. Notably, the experts also highlighted a remarkable ORR with Dato-DXd, showing that the ADC may be a robust treatment option for symptomatic patients or those experiencing rapid progression.They also discussed individualizing treatment between Dato-DXd and sacituzumab govitecan-hziy (Trodelvy) based on biomarker status, dosing schedules, and distinct toxicity profiles. Furthermore, the experts emphasized the importance of proactive management of unique ADC-associated toxicities. For Dato-DXd, they recommended prophylactic dexamethasone mouthwash and lubricating eye drops to mitigate mucositis and corneal surface events. For sacituzumab govitecan, they noted the necessity of growth factor support for neutropenia and loperamide for diarrhea.Regarding early-stage disease, they reaffirmed the phase 3 KEYNOTE-522 trial (NCT03036488) regimen of pembrolizumab (Keytruda) plus chemotherapy as the standard of care, with adjuvant escalation using capecitabine or PARP inhibitors for patients with residual disease.Drs Park and Iyengar concluded by spotlighting metabolic health interventions for patients with breast cancer. Although GLP-1 receptor agonists show promise in breast cancer survivors, Dr Iyengar cautioned against their initiation during active neoadjuvant immunotherapy due to their potential effects on pathologic complete response rates. He advocated for lifestyle interventions, including resistance training and a plant-forward, high-protein diet, to maintain lean muscle mass and improve OS outcomes.

Send us Fan MailA cancer diagnosis can change everything in an instant. One conversation. Three words: "You have cancer." Suddenly, patients and families are faced with uncertainty, fear, and countless questions about what comes next.In this episode of MedStar Health DocTalk, host Debra Schindler sits down with medical oncologist and hematologist Dr. Ankit Madan of MedStar Southern Maryland Hospital Center, to discuss the critical first steps after a cancer diagnosis. Dr. Madan explains how patients move from diagnosis to treatment, how cancer is staged, and why building a multidisciplinary care team is essential for the best possible outcomes.The conversation explores the emotional impact of hearing a cancer diagnosis, the importance of patient navigators, social workers, nutritionists, mental health professionals, and the role patients play as active partners in their own care. Dr. Madan also discusses treatment advances, clinical trials, immunotherapy breakthroughs, second opinions, and practical advice for patients and families navigating one of life's most challenging journeys.Whether you or a loved one has recently been diagnosed with cancer, this episode offers guidance, reassurance, and expert insight into what happens after the diagnosis—and how patients can move forward with confidence and support.Topics covered:• Coping with the emotional impact of a cancer diagnosis• Understanding cancer staging and treatment planning• The role of biopsies, CT scans, PET scans, and additional testing• Building a multidisciplinary cancer care team• Patient navigators, social workers, and support services• Shared decision-making and patient autonomy• When to seek a second opinion• Clinical trials and emerging cancer treatments• Immunotherapy and advances in cancer care• Nutrition, exercise, and mental health during treatment• Cancer survivorship and ongoing surveillanceTo learn more about cancer care at MedStar Health, visit MedStarHealth.org/Cancer.For more episodes of MedStar Health DocTalk, go to medstarhealth.org/doctalk.

In today's episode, we welcomed Joshua Richter, MD, to preview some of the top multiple myeloma presentations anticipated at the 2026 EHA Congress. Richter is an associate professor of medicine in the Division of Hematology and Medical Oncology at the Tisch Cancer Institute and director of Multiple Myeloma at the Blavatnik Family-Chelsea Medical Center at Mount Sinai in New York, New York.In the exclusive interview, Dr Ricther highlighted some of the key abstracts he's looking forward to seeing presented at EHA 2026, including primary data from an additional study of a bispecific antibody­–based combination being evaluated in the early-relapse setting and longer-term analyses from pivotal phase 3 studies. Richter also shared the key themes and trends he expects to see during the meeting in Stockholm, Sweden.

How This Is Building Me, hosted by world-renowned oncologist D. Ross Camidge, MD, PhD, is a podcast focused on the highs and lows, ups and downs of all those involved with cancer, cancer medicine, and cancer science across the full spectrum of life's experiences.In this episode, guest host Erin Schenk, MD, PhD, at the University of Colorado Anschutz in Aurora, an associate professor of medicine in the Division of Medical Oncology, sat down with D. Ross Camidge, MD, PhD, to highlight Dr Camidge's storied career and life. Driven by a relentless curiosity that often manifested in him "interrogating" those around him, Camidge chose a career in medicine because of the immediate effect he saw it could have on people's lives.His path included a formative gap year working at McDonald's and serving as a caregiver for a man with cerebral palsy. After studying at Oxford, he faced a significant professional and personal low when pursuing his PhD at Cambridge. Struggling with a difficult project, he persevered by pivoting his research and finding resilience through peers, eventually returning to practicing clinical medicine and finding his calling in oncology due to its unique overlap of molecular biology and opportunities for deep patient connection.Seeking further opportunities, Dr Camidge moved to the United States to lead the lung cancer program at the University of Colorado School of Medicine. He became a pivotal figure in the development of targeted therapies, specifically crizotinib for ALK-positive lung cancer. Beyond drug development, he championed the use of molecular profiling and established a global remote second opinion program.In 2022, Dr Camidge's perspective shifted profoundly following his own lung cancer diagnosis. This experience forced him to evolve from a "questioning machine" into someone more amenable to accepting love and support. He now integrates this dual perspective into his work, emphasizing that oncology must go beyond science to address the human experience of treating real people.

This episode is deeply personal to me.As the daughter of Indian immigrants, a breast surgeon, and a breast cancer survivor, I've seen firsthand how difficult it can be for our community to talk openly about health issues—especially breast cancer.Too often, conversations are delayed by fear, stigma, modesty, or the belief that we should simply "stay strong" and endure.But when it comes to breast cancer:

In this Part 1 of 2 ASCO 2026 Highlights episodes, hosts Dr. Narjust Florez and Dr. Stephen Liu are joined by Dr. Alice Shaw and Dr. Jonathan Goldman to review some of the most impactful targeted therapy data presented at the 2026 ASCO Annual Meeting. The discussion explores the practice-changing LIBRETTO-432 trial in early-stage RET-positive NSCLC, long-term outcomes with lorlatinib in ALK-positive disease, emerging data for neladalkib, and promising results for sunvozertinib in EGFR exon 20 insertion–positive NSCLC, highlighting how these findings may influence treatment decisions across disease stages. Guests: Dr. Alice Shaw. is a Professor of Medicine at Harvard Medical School, Chair of Medical Oncology, and a thoracic oncologist at Dana Farber Cancer Institute. She is widely recognized as a pioneer in the field of ALK-positive non-small cell lung cancer, having led landmark clinical trials that established crizotinib, ceritinib, and lorlatinib as standards of care. Dr. Jonathan W. Goldman is a Professor of Medicine and thoracic oncologist at the UCLA David Geffen School of Medicine, where he serves as a principal investigator in the Phase I drug development program. Dr. Goldman has been at the forefront of early-phase oncology trials across multiple tumor types, with a particular focus on novel therapeutics in lung cancer, and he was the presenting author of Libretto 432 at the plenary session at the 2026 ASCO

How This Is Building Me, hosted by world-renowned oncologist D. Ross Camidge, MD, PhD, is a podcast focused on the highs and lows, ups and downs of all those involved with cancer, cancer medicine, and cancer science across the full spectrum of life's experiences.In this episode, Dr Camidge sat down with Karen L. Reckamp, MD, director of Medical Oncology, associate director of Clinical Research, and the medical oncology director of the Lung Institute at Cedars Sinai in Los Angeles, California.Drs Camidge and Reckamp discussed Dr Reckamp's journey as an oncology specialist and now a caregiver for her husband, who has cancer. Reckamp's career was inspired by her family's history with BRCA-related cancers. She pursued an academic path that eventually led her to Los Angeles, where she became a leader in thoracic oncology during an era of genomic breakthroughs.In late 2024, her husband, a fellow oncologist, was diagnosed with pancreatic cancer shortly after a clear annual scan. Reckamp described the jarring transition of receiving the diagnosis and the ensuing emotions balanced with medical pragmatism. Bob underwent intensive treatments that have affected his physical health and daily life.Reckamp offered a candid look at the dual role of a physician-caregiver. She continues to work, however, her husband's cancer diagnosis has changed her practice. Now, she is more sensitive to chemotherapy toxicities in her patients that she might have previously minimized. She also highlighted the invisible load of caregivers who must manage their own emotions and remain available for patient needs.Ultimately, Reckamp emphasized the necessity of a support network, crediting their long-time nanny and overall community with maintaining her family's stability. By allowing different people to hold different pieces of the emotional burden, Reckamp shared that her family is finding a way to move forward amidst the uncertainty of this cancer diagnosis.

With the increasing incidence of colorectal cancer in those less than 50 years of age, one must wonder how many patients present with a Stage IV diagnosis. Take a deep dive with us discussing the management of metastatic colorectal cancer by joining our team and guests, Drs. Cathy Eng, Michael D'Angelica, and Nina Sanford.Hosts: - Dr. Janet Alvarez - General Surgery Resident at New York Medical College/Metropolitan Hospital Center- Dr. Wini Zambare – General Surgery Resident at Weill Cornell Medical Center/New York Presbyterian- Dr. Philip Bauer, Assistant Professor of Surgery, Division of Colon and Rectal Surgery, The Ohio State University Wexner Medical Center, Arthur G. James Cancer Hospital-  Dr. J. Joshua Smith MD, PhD, Chair, Department of Colon and Rectal Surgery at MD Anderson Cancer Center Guest Speakers:- Dr. Michael D'Angelica MD, FACS – Hepatopancreatobiliary Surgery, Memorial Sloan Kettering Cancer Center, Enid A. Haupt Chair in Surgery, Vice Chair, Education- Dr. Cathy Eng MD, FACP - Division of Hematology and Oncology, Vanderbilt-Ingram Cancer Center, David H. Johnson Endowed Chair in Surgical and Medical Oncology, Professor of Medicine, Hematology and Oncology, VICC Associate Director for Strategic Relations and Research Partnerships, Executive Director, Young Adult Cancers Program - Dr. Nina Sanford, MD – Radiation Oncology, UT Southwestern Medical Center, Chief of Gastrointestinal Radiation Oncology Service, Associate Professor Learning Objectives:1.     Review the epidemiology, prognosis, and common metastatic patterns of metastatic colorectal cancer (mCRC).2.     Discuss the role of systemic chemotherapy and targeted therapies in the first- and subsequent-line treatment of mCRC, including the impact of molecular biomarkers such as MSI/MMR, RAS, BRAF, and HER2.3.     Evaluate the indications and timing of surgical and locoregional therapies for metastatic colorectal cancer, particularly in patients with liver-limited or oligometastatic disease.4.     Describe the multidisciplinary management of mCRC, including the roles of radiation therapy, systemic therapy sequencing, and palliative interventions to optimize outcomes and quality of life.References:Singh, M., Morris, V. K., Bandey, I. N., Hong, D. S. & Kopetz, S. Advancements in combining targeted therapy and immunotherapy for colorectal cancer. Trends Cancer 10, 598–609 (2024). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/38821852/Napolitano, S. et al. BRAFV600E mutant metastatic colorectal cancer: Current advances in personalized treatment and future perspectives. Cancer Treat. Rev. 134, (2025). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40009904/Ciardiello, F. et al. Clinical management of metastatic colorectal cancer in the era of precision medicine. CA. Cancer J. Clin. 72, 372–401 (2022). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/35472088/Kim, S. Y. & Kim, T. W. Current challenges in the implementation of precision oncology for the management of metastatic colorectal cancer. ESMO Open 5, e000634 (2020). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/32188714/Biller, L. H. & Schrag, D. Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review. JAMA 325, 669–685 (2021). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/33591350/Smith, J. J. et al. Genomic stratification beyond Ras/B-Raf in colorectal liver metastasis patients treated with hepatic arterial infusion. Cancer Med. 8, 6538–6548 (2019). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/31503397/Saadat, L. V. et al. Hepatic Artery Infusion Chemotherapy Compared to Transarterial Radioembolization For Unresectable Colorectal Liver Metastases. Ann. Surg. 10.1097/SLA.0000000000006851 doi:10.1097/SLA.0000000000006851. PubMed Link: https://pubmed.ncbi.nlm.nih.gov/?term=10.1097/SLA.0000000000006851 (Linked via DOI search as the direct PMID is still indexing)Xiao, A. & Fakih, M. KRAS G12C Inhibitors in the Treatment of Metastatic Colorectal Cancer. Clin. Colorectal Cancer 23, 199–206 (2024). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/38825433/André, T. et al. Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer. N. Engl. J. Med. 383, 2207–2218 (2020). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/33264544/Morris, V. K. et al. Treatment of Metastatic Colorectal Cancer: ASCO Guideline. J. Clin. Oncol. 41, 678–700 (2023). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/36252154/Xu, Z. et al. Treatments for Stage IV Colon Cancer and Overall Survival. J. Surg. Res. 242, 47–54 (2019). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/31071604/Smith, J. J. & D'Angelica, M. I. Surgical Management of Hepatic Metastases of Colorectal Cancer. Hematol. Oncol. Clin. North Am. 29, 61–84 (2015). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/25475573/Strickler, J. H. et al. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. Lancet Oncol. 24, 496–508 (2023). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/37142372/Kruijssen, D. E. W. van der et al. Upfront resection versus no resection of the primary tumor in patients with synchronous metastatic colorectal cancer: the randomized phase III CAIRO4 study conducted by the Dutch Colorectal Cancer Group and the Danish Colorectal Cancer Group. Ann. Oncol. 35, 769–779 (2024). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/38852675/Hitchcock, K. E., Romesser, P. B. & Miller, E. D. Local Therapies in Advanced Colorectal Cancer. Hematol. Oncol. Clin. North Am. 36, 553–567 (2022). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/35562258/Hitchcock, K. E. et al. Alliance for clinical trials in Oncology (Alliance) trial A022101/NRG-GI009: a pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer: evaluating radiation, ablation, and surgery (ERASur). BMC Cancer 24, 201 (2024). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/38350888/Adam, R. et al. Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): results from a multicentre, open-label, prospective, randomised controlled trial. The Lancet 404, 1107–1118 (2024). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/39306468/Elez, E. et al. Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer. N. Engl. J. Med. 392, 2425–2437 (2025). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40444708/***Fellowship Application Link: https://forms.gle/QSUrR2GWHDZ1MmWC6Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listenBehind the Knife Premium:General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-reviewTrauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlasDominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkshipDominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotationVascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-reviewColorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-reviewSurgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-reviewCardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-reviewDownload our App:Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US